Trends and Dynamics of the Biosimilar Market across the EU, Latin America and Asia Pacific Regions
CBPartners' Pharma Take-Away
by CBPartners
2y ago
Following on from the previous podcast episode involving a discussion on the US biosimilar landscape, CBPartners’ experts explored trends and dynamics of the biosimilar market ex-USA – across the EU, Latin America and Asia, with a focus on:  Biosimilar availability and uptake in each region  Key barriers limiting biosimilar approval and uptake     Biosimilar manufacturer strategies to ensure successful launch  ..read more
Visit website
Opportunities and Barriers for Biosimilar Uptake in the USA
CBPartners' Pharma Take-Away
by CBPartners
3y ago
As the costs of biologic drugs increase, biosimilars have emerged as an appealing option for controlling costs and expanding access to treatment. While the uptake of biosimilars in the USA started off slowly, it has since gained a rapid pace.  In the first of a multi-part biosimilar series, this episode will explore the evolving biosimilar landscape, including the opportunities and barriers for uptake, as well as the future outlook for biosimilars in the USA. Topics covered include:  Current biosimi ..read more
Visit website
USA Policy Expectations for a New Administration
CBPartners' Pharma Take-Away
by CBPartners
3y ago
During the 2020 US Presidential Election, several campaign promises, policies, and healthcare reforms were presented by both the Republican and Democratic parties. Since winning the election, President Biden, his new administration, and the new democrat-controlled congress have prioritized  efforts to combat the COVID-19 pandemic. However, the administration has not been idle in targeting broader changes promised on the campaign trail, including meaningful expansions to the Affordable Care Act layered into their la ..read more
Visit website
Digital Health (pt 3): Emergence of Companion Digital Treatments and Standalone Digital Therapeutics
CBPartners' Pharma Take-Away
by CBPartners
3y ago
The rapid growth of digital therapeutics (DTx) in healthcare has seen the emergence of both companion digital treatments and standalone DTx in the market. The development and commercialization of standalone DTx in particular offers an interesting perspective on the reimbursement challenges and regulatory barriers that DTx faces as it continues to expand into new disease spaces and the healthcare market. In part 3 of the digital health series, this latest CBPartners podcast episode, hosted by Akhil Parlapalli, provides an engaging discussion with guests Matthew Rube, Jeremy Guild, and Nelli Mor ..read more
Visit website
Digital Health (pt 2): New Medical Technologies and Clinical Trials
CBPartners' Pharma Take-Away
by CBPartners
3y ago
Digital health is set to transform the collection and sharing of data which could be used in the assessment of new medical technologies. The proliferation of digital health tools has helped to drive innovation in digital therapeutics, clinical trials, and healthcare. In CBPartners’ latest podcast, part 2 of the digital health series, Jared Louis Wolff, MS, Matt Rube and Akhil Parlapalli discuss how manufacturers can leverage technology in the clinical trial landscape, including:  Digital health tools and data collection The challenges and successes of incorporating digital health approac ..read more
Visit website
Digital Health (Pt 1): Current Landscape and Payer Dynamics
CBPartners' Pharma Take-Away
by CBPartners
3y ago
The number of virtual medical consultations when compared to in-person consultations is growing dramatically year-on-year. As such, the ‘digital medicine’ trend is revolutionizing healthcare delivery as we know it – and the transition, partially from necessity due to the COVID-19 pandemic, is happening sooner than expected. In CBPartners’ latest podcast, Jared Louis Wolff, MS, Luke Wiggins, and Temi Coker discuss the rise of digital health and telemedicine, and what this means for patients, physicians, and insurers, including: How patients and physicians are adapting to telemed ..read more
Visit website
Alzheimer's and Aducanumab: The Beta Amyloid Theory's Last Hope
CBPartners' Pharma Take-Away
by CBPartners
3y ago
Despite $2.8 billion allocated by the NIH to Alzheimer's research in 2020 alone, results to date have been rocky. Why is this disease that affects millions of people so tough to crack? This episode of CBPartners’ podcast seeks to answer this question as healthcare consultant Jared Wolff, is joined by Sophie Katz, and Anna Du, as they delve into: The primary focus of Alzheimer’s research and treatments Likelihood assessment of the FDA approving Biogen’s aducanumab  High value AD targets that should be a future focus We hope you enjoy the content and thanks for listening!  ..read more
Visit website
Digital Health (pt 3): Emergence of Companion Digital Treatments and Standalone Digital Therapeutics
CBPartners' Pharma Take-Away
by CBPartners
3y ago
The rapid growth of digital therapeutics (DTx) in healthcare has seen the emergence of both companion digital treatments and standalone DTx in the market. The development and commercialization of standalone DTx in particular offers an interesting perspective on the reimbursement challenges and regulatory barriers that DTx faces as it continues to expand into new disease spaces and the healthcare market. In part 3 of the digital health series, this latest CBPartners podcast episode, hosted by Akhil Parlapalli, provides an engaging discussion with guests Matthew Rube, Jeremy Guild, and Nelli Mor ..read more
Visit website
COVID-19 (Pt 3): Testing
CBPartners' Pharma Take-Away
by CBPartners
3y ago
This final episode of the COVID-19 trilogy focuses on testing. Specifically, the different types of tests available for COVID-19 and the regulatory environment in which these tests exist. How will an accurate test change how healthcare experts respond to the disease? Healthcare consultant Jared Wolff is joined by the COVID-19 Podcast Team, Matthew Rube and Akhil Parlapalli, to discuss themes about:   Testing Basics  Regulatory Environment and Implications  Big Pharma Moves and Updated for Treatment, Vaccines, and Testing  We wo ..read more
Visit website
Digital Health (pt 2): New Medical Technologies and Clinical Trials
CBPartners' Pharma Take-Away
by CBPartners
3y ago
Digital health is set to transform the collection and sharing of data which could be used in the assessment of new medical technologies. The proliferation of digital health tools has helped to drive innovation in digital therapeutics, clinical trials, and healthcare. In CBPartners’ latest podcast, part 2 of the digital health series, Jared Louis Wolff, MS, Matt Rube and Akhil Parlapalli discuss how manufacturers can leverage technology in the clinical trial landscape, including:  Digital health tools and data collection The challenges and successes of incorporating digital health approac ..read more
Visit website

Follow CBPartners' Pharma Take-Away on FeedSpot

Continue with Google
Continue with Apple
OR